Effective Cancer Treatments That Can Reduce Tumor Markers in less than 3 Months

Ms Lai Yen Kam, Malaysia, a 64-year-old patient diagnosed with ER-positive, HER2-negative breast cancer with confirmed lung metastasis, began treatment in May 2025 following a period of clinical observation. Her disease presented with a large right breast mass (6.9 cm), axillary lymphadenopathy, and several metastatic lung nodules.

On 12 May 2025, she initiated a combination of Palbociclib and Letrozole, a well-established regimen for hormone receptor–positive metastatic breast cancer. One week later, on 19 May 2025, she added ECCT to her treatment plan. ECCT was used as a complementary approach to enhance treatment effect without introducing toxicity.

Over the following 6 weeks, Ms Lai demonstrated remarkable tumour marker improvement. This significant reduction strongly indicates a favourable response at the biochemical level. ECCT appeared to complement systemic treatment effectively, contributing to biological improvement and physical stability in Stage IV breast cancer.

Clinically, she remained stable and functional. Her daily activity, including brisk walking, was unaffected. She did not experience any side effects typically associated with chemotherapy or radiotherapy. Respiratory function, previously compromised due to a left pneumothorax, remained stable with no further complications post-pleurodesis.

Hope her journey helps to motivate some others particularly in patients who wish to prioritize quality of life, who wish to reduce systemic toxicity side effect and hasten reduction of tumour activity.